About: Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.42 (-2.71%)
RLMD NASDAQ Relmada Therapeutics Inc
Relmada Therapeutics Inc share price
RLMD price activity
Last Price
$3.420
Change (24hr)
-0.10 USD (-2.71%)
Volume
630.03K
Volume (4w avg)
-
Open
$3.50
Day Range
$3.42 - $3.50
Previous Close
$3.51
Last Trade
13 Oct, 5:31 pm GMT+0
Delayed
13 Oct, 5:31 pm GMT+0
RLMD price performance
Delayed
13 Oct, 5:31 pm GMT+0
RLMD Market Signals